Best Life Sciences Companies in Louisville, United States

Developer of therapeutics for the treatment of multiple diseases. The company's drugs include APOKYN (apomorphine hydrochloride injection for Parkinson's disease), CORGARD (nadolol tablets for hypertension, angina pectoris), MYOBLOC (rimabotulinumtoxinB Injection for cervical dystonia), REVONTO (dantrolene sodium injection for anesthetic-induced malignant hyperthermia syndrome) and XADAGO (safinamide tablets for Parkinson's Disease).

Developing respiratory muscle stimulator technology to liberate patients from mechanical ventilation. The company focuses on creating innovative solutions for mechanically ventilated patients, addressing the unmet need of respiratory muscle atrophy. Their VentFree Respiratory Muscle Stimulator uses non-invasive neuromuscular electrical stimulation to contract abdominal wall muscles, synchronized with exhalation. This therapy aims to reduce muscle atrophy and potentially decrease the duration of mechanical ventilation. The company's technology has received regulatory authorization for emergency use, highlighting its potential to improve clinical outcomes, reduce morbidity and mortality, and offer significant savings for healthcare providers. They are committed to advancing respiratory care through research, development, and a focus on patient well-being.

Developer of freeze-dried blood product for blood transfusion. The company is developing freeze-dried red blood cells that can be stored and infused to patients experiencing traumatic blood loss, especially in remote or battlefield settings.

Funding rounds

• Mar 2026Series A$840K
• Jul 2024Series A$5.2M
• Feb 2023Grant (prize money)$281.9K

Founders & team

Jonathan KopechekCo-FounderBrett JanisCo-Founder & CEO

Investors

HHS

3P Biotechnologies has developed the patented technology for exosome extraction from bovine milk and colostrum. The platform also developing a uterine cervical implant device called PolyC. This device helps in the continuous local release of drugs in cervical cancer disease. The platform also extracted the drug called ANTHOS from the biberry extracts.

Funding rounds

• Aug 2025Grant (prize money)$506.5K
• Mar 2025Grant (prize money)$506.5K
• Sep 2024Grant (prize money)$500K
• Sep 2024Grant (prize money)$506.5K

Founders & team

Ramesh GuptaFounder & President

Investors

KY Innovation, HHS

Developer of an artificial cervical disc for degenerative disc disease. The company offers Synergy Disc which is designed to restore physiological motion and correct sagittal balance.

Funding rounds

• Dec 2024Series A$406.1K
• Jan 2024Series A$30M

Founders & team

Josh ButtersCEO

Investors

Amzak Health

Tech stack

Apple Icloud MailCloudflareCloudflare Bot ManagementContact Form 7Core-JsFlywheel

Developer of a small molecule drug targeting chronic inflammatory diseases. The company's lead asset is an FDA-designated orphan drug intended to address an unmet need. The company focuses on developing therapeutics for inflammatory bowel disease, viral and infectious diseases, metabolic and cardiovascular diseases, neuro-degenerative diseases, and autoimmune diseases. The leadership team has experience in healthcare and life sciences.

Funding rounds

• Apr 2026Seed$100K
• Sep 2025Seed$50K

Founders & team

David McClureCo-Founder & COOTad DrydenCo-FounderTerry MintonCo-Founder & CEO

Peptide therapeutics innovator targeting metabolic diseases with custom synthesis services. The company discovers peptide therapeutics for metabolic disease, employing advanced in-silico techniques to design novel peptides and proprietary technology to efficiently generate them. They offer custom synthesis services and a portfolio of peptides to customers seeking high purity solutions. The goal is to license drug candidates at or before the Investigational New Drug stage. They leverage capabilities to develop therapeutics targeting metabolic diseases. They provide solutions to the biopharmaceutical industry and research community. They are focused on research and drug development, offering a pipeline of pre-clinical drug candidates. They are a B2B company in the biotechnology industry.

Minimally invasive surgical solution for specimen removal, improving patient outcomes. This company focuses on developing a fast, easy, and safe solution for minimally invasive specimen removal, addressing the need to minimize incision sizes during surgery. Driven by advancements in surgical robotics, they aim to provide patients with less pain, shorter hospital stays, and quicker return to normal activities. Their fully contained device offers a minimally invasive specimen removal option, ensuring incisions remain small throughout the entire procedure. This innovative approach enhances patient care and recovery in the field of minimally invasive surgery.

Funding rounds

• Mar 2023Series A$15.3M
• Feb 2020Series A$17M
• Mar 2018Series A$5.1M
• Dec 2017Seed$1.2M

Founders & team

Donna Ford-SerbuCo-Founder & CEO

Investors

Questa Capital, Venture Investors, MedTech Innovator, Springboard Enterprises, ForMED Ventures, Innosphere

Talaris Therapeutics is involved in developing single-dose cell therapy to treat living donor kidney transplant tolerance. They have developed a proprietary technology that allows candidates for bone marrow transplants to receive hematopoietic stem cells (HSCs). The lead candidate FCR001, is in phase III clinical trial, which is being investigated for living donor kidney transplant tolerance.

GlobeImmune engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. A Tarmogen consists of intact, heat-inactivated yeast containing a target protein. Immunization with a Tarmogen results in antigen-specific cellular immune responses against the target protein and reduction in the number of abnormal cells containing the same target antigen. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies.

Provider of early warning blood tests for pregnancy complications. The company's assays leverage its proprietary NeXosome platform technology which enables the isolation and enrichment of exosome and microvesicle particles from bodily fluids for non-invasive biomarker evaluation.

Funding rounds

• Aug 2023Series A$3.1M
• Oct 2022Grant (prize money)—
• Nov 2020Seed$72K
• May 2020Seed$2.1M

Founders & team

Brian BrohmanCo-Founder & Co-CEOGail S PageCo-CEO

Investors

Johnson & Johnson Innovation, BELLE Impact Fund, XLerateHealth, Golden Seeds, Mindshift Capital, Michbelles

Tech stack

WebflowCloudflareRecaptchaJsdelivrJqueryGoogle Analytics

Bolder Surgical provides small-sized electrosurgical devices for pediatric patients. They have developed the world's first 5mm mechanical stapler with a pediatric indication. Its product includes JustRight 5mm Stapler, EcoSac 5mm Tissue Retrieval System, and JustRight Vessel Sealing System.